Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych |

URPLWMiPB

URPLWMiPB

Signing of a cooperation agreement with the Agency for Medicines and Medical Devices in Moldova (AMDM)

16/03/2023
Communication of the President of the Office of 23 January 2023 on the publication of a joint statement of the Medicines Shortages Steering Group (MSSG) on shortages of antibiotic medicines.

23/01/2023
118th meeting of the Management Board of the European Medicines Agency

20/12/2022
Communication of the President of the Office of 6 December 2022 on the EMA's ETF recommendation on the use of a bivalent adapted vaccine against Omicron BA.4/5 subvariants and original SARS-CoV-2 virus in primary vaccination.

06/12/2022
Communication of the President of the Office, of 25.11.2022, on the CHMP recommendation, of 10.11.2022, for the authorisation of the booster vaccine VidPrevtyn Beta for adults previously vaccinated with the vector or mRNA vaccine against COVID-19.

25/11/2022
Communication of the President of the Office of 20 October 2022 on the recommendation of the Committee for Medicinal Products for Human Use (CHMP) EMA on the use of COVID-19 Comirnaty and Spikevax vaccines in children aged 6 months and older.

20/10/2022
Communication of the President of the Office of 20 October 2022 on the recommendation of the EMA's Committee for Medicinal Products for Human Use (CHMP) to authorise the marketing of the second adapted bivalent vaccine Spikevax against...

20/10/2022